Table 5.

Change in mean HbA1c during dosing period (ITT and PP populations).

	5-ALA-SFC			Placebo
	n	Mean	Change from baselinea  Mean (SE)	n	Mean	Change from baselinea   Mean (SE)
Intent-to-treat population
Week 2	32	7.6	−0.2∗ (0.1)	13	7.4	−0.5∗ (0.2)
Week 4	30	7.5	−0.3∗ (0.1)	13	7.3	−0.5∗ (0.2)
Week 6	28	7.3	−0.4∗ (0.1)	13	7.2	−0.6∗ (0.2)
Week 12	25	7.1	−0.7∗ (0.2)	13	7.3	−0.5 (0.2)
Per protocol population
Week 2	15	7.3	−0.3∗ (0.1)	6	7.6	−0.3 (0.2)
Week 4	15	7.1	−0.4∗ (0.1)	7	7.3	−0.5 (0.2)
Week 6	14	7.1	−0.4∗ (0.1)	7	7.2	−0.6 (0.2)
Week 12	14	6.8	−0.8∗ (0.2)	7	7.3	−0.5 (0.3)

^∗ p < 0.05 compared to baseline.

^aCompared to baseline mean for only the subjects with a result for the visit.